CAPITOL COUNSEL LLC for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CAITLIN CANTER | — |
Health Issues HCR
340B issues and patient access to pharmaceuticals. Coronavirus response efforts, including related provisions in H.R. 6800, the HEROES Act; H.R. 8406, the Heroes Act; S. 4318, the American Workers, Families, and Employers Assistance Act; S. 4320, the Coronavirus Response Additional Supplemental Appropriations Act, 2020; and S. 4322, the Safely Back to School and Back to Work Act. Legislative issues associated with patient access to treatment and the Presidents Executive Orders on: (1) Lowering Drug Prices by Putting America First; (2) Lowering Prices for Patients by Eliminating Kickbacks to Middlemen; (3) Increasing Drug Importation to Lower Prices for American Patients; and (4) Access to Life Saving Medications. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines; and improved coordination and expansion of mutual reliance agreements.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CAITLIN CANTER | — |
| AARON COHEN | — |
| SHANNON FINLEY | — |
| SARA FRANKO | — |
| MARTIN B. GOLD | — |
| LUKE HATZIS | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
Medicare/Medicaid MMM
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, including related provisions modifying Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements in H.R. 3, the Lower Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act; use of step therapy in Medicare and health insurance coverage. Coronavirus response efforts, including related provisions in H.R. 6800, the HEROES Act; H.R. 8406, the Heroes Act; S. 4318, the American Workers, Families, and Employers Assistance Act; S. 4320, the Coronavirus Response Additional Supplemental Appropriations Act, 2020; and S. 4322, the Safely Back to School and Back to Work Act. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including related provisions in H.R. 5741, the Strengthening Innovation in Medicare and Medicaid Act. Legislative issues associated with patient access to treatment and the Presidents Executive Orders on: (1) Lowering Drug Prices by Putting America First; (2) Lowering Prices for Patients by Eliminating Kickbacks to Middlemen; (3) Increasing Drug Importation to Lower Prices for American Patients; and (4) Access to Life Saving Medications.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CAITLIN CANTER | — |
| AARON COHEN | — |
| SHANNON FINLEY | — |
| SARA FRANKO | — |
| MARTIN B. GOLD | — |
| LUKE HATZIS | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.